Literature DB >> 27681116

Oxytocin, cortisol and 3,4-methylenedioxymethamphetamine: neurohormonal aspects of recreational 'ecstasy'.

Andrew C Parrott1.   

Abstract

Most research into 3,4-methylenedioxymethamphetamine (MDMA) has debated its psychobiological effects in relation to neurotransmission. This article debates the contributory roles of the neurohormones oxytocin and cortisol for their psychobiological effects in humans. The empirical literature on these neurohormones is reviewed and suggestions for future research outlined. Acute MDMA or 'ecstasy' can generate increased levels of oxytocin and cortisol, and these neurohormonal changes may be important for its mood-enhancing and energy-activation effects in humans. However, an initial finding of enhanced sociability correlating with oxytocin levels has not been replicated. Potential reasons are debated. There may be dynamic interactions between the two neurohormones, with greater activation under cortisol, facilitating stronger positive feelings under oxytocin. Chronic regular use of MDMA can adversely affect cortisol in several ways. Regular users show increased cortisol in 3-month hair samples, changes to the cortisol awakening response, and indications of greater daily stress. Furthermore, these cortisol findings suggest changes to the hypothalamic-pituitary-adrenal axis. The effects of chronic MDMA usage on oxytocin still need to be investigated. It is concluded that the neurohormones oxytocin and cortisol contribute in various ways to the psychobiological effects of recreational ecstasy/MDMA.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27681116     DOI: 10.1097/FBP.0000000000000262

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  8 in total

Review 1.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

Review 2.  (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA.

Authors:  Elizabeth G Pitts; Daniel W Curry; Karly N Hampshire; Matthew B Young; Leonard L Howell
Journal:  Psychopharmacology (Berl)       Date:  2017-12-16       Impact factor: 4.530

Review 3.  Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy.

Authors:  Hans Emanuel Oeri
Journal:  J Psychopharmacol       Date:  2020-09-10       Impact factor: 4.153

Review 4.  Mood Fluctuation and Psychobiological Instability: The Same Core Functions Are Disrupted by Novel Psychoactive Substances and Established Recreational Drugs.

Authors:  Andrew C Parrott
Journal:  Brain Sci       Date:  2018-03-13

5.  Oxytocin receptor gene variations and socio-emotional effects of MDMA: A pooled analysis of controlled studies in healthy subjects.

Authors:  Patrick Vizeli; Matthias E Liechti
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

6.  Comparative Untargeted Metabolomics Analysis of the Psychostimulants 3,4-Methylenedioxy-Methamphetamine (MDMA), Amphetamine, and the Novel Psychoactive Substance Mephedrone after Controlled Drug Administration to Humans.

Authors:  Andrea E Steuer; Daria Kaelin; Martina I Boxler; Lisa Eisenbeiss; Friederike Holze; Patrick Vizeli; Joanna Czerwinska; Paul I Dargan; Vincenzo Abbate; Matthias E Liechti; Thomas Kraemer
Journal:  Metabolites       Date:  2020-07-27

7.  MDMA treatment paired with a trauma-cue promotes adaptive stress responses in a translational model of PTSD in rats.

Authors:  Shira Arluk; Michael A Matar; Lior Carmi; Oded Arbel; Joseph Zohar; Doron Todder; Hagit Cohen
Journal:  Transl Psychiatry       Date:  2022-05-03       Impact factor: 7.989

8.  Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects.

Authors:  Patrick Vizeli; Isabelle Straumann; Urs Duthaler; Nimmy Varghese; Anne Eckert; Martin P Paulus; Victoria Risbrough; Matthias E Liechti
Journal:  Front Pharmacol       Date:  2022-07-13       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.